Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Brain tumor, child: Brain stem glioma
Stage/Subtype:  recurrent childhood brain stem glioma
Country:  U.S.A.
Trial Type:  Treatment
Trial Status:  Active
Results 1-22 of 22 for your search:
Start Over
Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 1 to 25
Sponsor: NCI, Other
Protocol IDs: 2013-062, NCI-2013-02001, P30CA022453, NCT01987596
Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 21
Sponsor: NCI, Other
Protocol IDs: ADVL0912, COG-ADVL0912, CDR0000647587, NCT00939770
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 12 to 21
Sponsor: NCI
Protocol IDs: NCI-2012-03173, CDR667932, PBTC-029B, PBTC-029, U01CA081457, UM1CA081457, NCT01089101
Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 4 to 21
Sponsor: Other
Protocol IDs: 10-096, NCT01294670
Diffuse Intrinsic Pontine Glioma (DIPG) Reirradiation (ReRT)
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 17 and under
Sponsor: Other
Protocol IDs: 2011-0804, NCI-2011-03725, NCT01469247
Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 2 to 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: TED12689, U1111-1128-5704, NCT01751308
Phase I/II Trial Of Super-Selective Intraarterial Infusion Of Erbitux and Bevacizumab For Treatment Of Relapsed/Refractory Intracranial Glioma In Patients Under 22 Years Of Age
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Under 22
Sponsor: Other
Protocol IDs: 1202012214, NCT01884740
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: 05-122, MSKCC-05122, NCT00445965
Antineoplaston Therapy in Treating Children With Brain Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: 6 months to 17 years
Sponsor: Other
Protocol IDs: CDR0000066490, BC-BT-10, NCT00003458
A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 0 to 21
Sponsor: Other
Protocol IDs: Poly ICLC, 004385, NCT01188096
Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma
Phase: Phase II
Type: Treatment
Status: Active
Age: 3 to 18
Sponsor: Other
Protocol IDs: NMTRCPG007, NCT01774253
A Trial of Everolimus and Bevacizumab in Children With Recurrent Solid Tumors
Phase: Phase I
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: RADBEV, NCI-2011-01149, NCT00756340
Convection-Enhanced Delivery of 124I-8H9 for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy
Phase: Phase I
Type: Treatment
Status: Active
Age: 3 to 21
Sponsor: Other
Protocol IDs: 11-011, NCT01502917
Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG)
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 2 to 21
Sponsor: Other
Protocol IDs: SJHG12, NCI-2012-01240, NCT01644773
Photodynamic Therapy (PDT) for Brain Tumors
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and under
Sponsor: Other
Protocol IDs: 163588-1, NCT01682746
Intra-arterial Chemotherapy for the Treatment of Progressive Diffuse Intrinsic Pontine Gliomas (DIPG).
Phase: Phase I
Type: Treatment
Status: Active
Age: 1 month to 17 years
Sponsor: Other
Protocol IDs: J11164, NA_00069122, NCT01688401
Dendritic Cell Vaccine For Malignant Glioma and Glioblastoma Multiforme in Adult and Pediatric Subjects
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 13 to 99
Sponsor: Other
Protocol IDs: 20120750, NCT01808820
NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 2 to 25
Sponsor: NCI
Protocol IDs: 130152, 13-C-0152, NCT01875601
Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 4 to 21
Sponsor: NCI, Other
Protocol IDs: PBTC-042, U01CA081457, NCT02255461
Prospective Assessment of Quality of Life (QOL) in Pediatric Patients Treated With Radiation Therapy for Brain Tumors and Non-central Nervous System (Non-CNS) Malignancies
Phase: No phase specified
Type: Natural history/Epidemiology, Treatment
Status: Active
Age: 2 to 25
Sponsor: Other
Protocol IDs: 2005P001629, NCT01115777
A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction With Poly-ICLC in Pediatric Gliomas
Phase: No phase specified
Type: Treatment
Status: Active
Age: 19 months to 20 years
Sponsor: Other
Protocol IDs: PRO08030085, NCT01130077
Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 month to 29 years
Sponsor: Other
Protocol IDs: SC-9006, NCT02015728
Start Over